Ornithine Transcarbamylase OTC Deficiency Treatment Market: How Are Gene Therapies and Novel Nitrogen Scavengers Transforming Urea Cycle Disorder Management?
Ornithine transcarbamylase deficiency — the most common urea cycle disorder (X-linked, estimated incidence 1:14,000-1:77,000 live births) causing hyperammonemic crises, neurocognitive decline, and life-threatening metabolic decompensation — has historically relied on protein restriction, ammonia scavengers, and liver transplantation, but the Ornithine Transcarbamylase OTC Deficiency...
0 Comments 0 Shares 222 Views 0 Reviews
Sponsored
Sponsored